NSE - Delayed Quote INR

Brooks Laboratories Limited (BROOKS.NS)

Compare
141.55 -2.45 (-1.70%)
At close: 3:14 PM GMT+5:30
Loading Chart for BROOKS.NS
DELL
  • Previous Close 144.00
  • Open 144.00
  • Bid --
  • Ask --
  • Day's Range 141.55 - 144.00
  • 52 Week Range 73.25 - 185.70
  • Volume 6,886
  • Avg. Volume 71,976
  • Market Cap (intraday) 3.715B
  • Beta (5Y Monthly) 1.54
  • PE Ratio (TTM) --
  • EPS (TTM) -7.70
  • Earnings Date Jan 29, 2025 - Feb 3, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Brooks Laboratories Limited manufactures and sells pharmaceuticals in India and internationally. The company offers liquid and dry powder injection, carbapenem dry powder injectables, tablets, oral suspension, dry syrup, and eye/ear drops. Brooks Laboratories Limited was incorporated in 2002 and is based in Mumbai, India.

www.brookslabs.net

293

Full Time Employees

March 31

Fiscal Year Ends

Recent News: BROOKS.NS

View More

Performance Overview: BROOKS.NS

Trailing total returns as of 11/28/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

BROOKS.NS
1.43%
S&P BSE SENSEX
9.42%

1-Year Return

BROOKS.NS
10.11%
S&P BSE SENSEX
19.82%

3-Year Return

BROOKS.NS
37.94%
S&P BSE SENSEX
38.41%

5-Year Return

BROOKS.NS
449.75%
S&P BSE SENSEX
92.69%

Compare To: BROOKS.NS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: BROOKS.NS

View More

Valuation Measures

Annual
As of 11/27/2024
  • Market Cap

    3.78B

  • Enterprise Value

    3.85B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    4.80

  • Price/Book (mrq)

    6.38

  • Enterprise Value/Revenue

    4.95

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -21.46%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    817.16M

  • Net Income Avi to Common (ttm)

    -175.35M

  • Diluted EPS (ttm)

    -7.70

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    6.93M

  • Total Debt/Equity (mrq)

    8.60%

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: BROOKS.NS

View More

Company Insights: BROOKS.NS

Research Reports: BROOKS.NS

View More

People Also Watch